All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML
During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Has the role of haploidentical transplant changed in AML?
Has the role of haploidentical transplant changed in AML?
Haploidentical transplantation has revolutionized the field, as it offers the opportunity of a donor to almost every patient in need of transplant. In this video, Nagler discusses the benefits of haploidentical transplantation for patients with AML.
EHA 2019 | Should we use PTCy or ATG as GvHD prophylaxis in haploidentical stem cell transplantation?
Arnon Nagler from the Tel Aviv Univesity, Tel Aviv, IL, discusses whether prophylactic post-transplant cyclophosphamide (PTCy) or anti-thymocyte...
Arnon Nagler | EBMT 2019 | Haploidentical hematopoietic transplantation: current status and future perspectives
Arnon Nagler, from Tel Aviv University, IL, discusses haploidentical hematopoietic transplantation: current status and future perspectives
Subscribe to get the best content related to AML delivered to your inbox